Prognose

Analytikernes gennemsnitlige kursmål er 44,24 € (+125,03 %). Medianen er 43,95 € (+123,55 %).

Køb	9
Behold	1
Sælg	0

Nyheder Til nyhedsfeedet

NewAmsterdam Pharma prepares launch of Obicetrapib and expects pivotal study data

At the Cantor conference NewAmsterdam Pharma outlined the upcoming critical phase for Obicetrapib, with an interim analysis of the PREVAIL study expected in early 2025 and an anticipated European approval following a positive CHMP recommendation. Management emphasized broad clinical effects beyond LDL reduction and plans phased launches through partner Menarini alongside a moderate expansion of its commercial infrastructure. The stock fell to $22.14 after the presentation, but the company stresses disciplined spending and expects R&D costs to decline through 2027. » Mere på de.investing.com
NewAmsterdam Pharma presents Obicetrapib at Wells‑Fargo conference as differentiated cholesterol‑lowering drug

At the Wells‑Fargo healthcare conference, NewAmsterdam emphasized the multiple effects of Obicetrapib — strong LDL reduction, HDL increase, Lp(a) reduction and potential benefits on diabetes and Alzheimer biomarkers — and highlighted positive BROADWAY data showing a 21% relative risk reduction for 4‑point MACE. The approval‑relevant phase‑III trial PREVAIL has been redesigned; an interim analysis is expected in Q4 2024 and a DSMB recommendation in Q1 2027. A U.S. regulatory filing and market launch are planned 12–18 months after PREVAIL completion. No financial figures were disclosed; management views Obicetrapib as a complementary therapy to PCSK9 treatments and announced further studies such as RUBIN (diabetes) and SPINOZA (Alzheimer). » Mere på de.investing.com

Virksomhedstal

I det seneste kvartal havde NewAmsterdam Pharma Company N.V. en omsætning på 3,24 mio. € og et nettoresultat på -56,2 mio. €

(EUR)	juni 2026	YoY
Omsætning	3,24 mio.	80,04 %
Bruttofortjeneste	3,24 mio.	80,04 %
Nettoresultat	-56,2 mio.	281,45 %
EBITDA	-52,3 mio.	255,96 %

Fundamentale data

Nøgletal	Værdi
Markedsværdi	2,3 mia. €
Antal aktier	116,9 mio.
Højeste/laveste i 52 uger	36,37 € - 18,30 €
Udbytte	Nej
Beta	0,10
P/E (PE Ratio)	-10,46
PEG (PEG Ratio)	0,31
K/I (PB Ratio)	4,45
P/S (PS Ratio)	374,30

Virksomhedsprofil

NewAmsterdam Pharma Company N.V., ein biopharmazeutisches Unternehmen im klinischen Stadium, konzentriert sich auf die Verbesserung der Patientenversorgung in Bevölkerungsgruppen mit Stoffwechselkrankheiten. Sein führender Prüfkandidat, Obicetrapib, ist ein neuartiger, selektiver Hemmstoff, der auf das Cholesteryl-Ester-Transferprotein (CETP) abzielt, das klinisch erwiesenermaßen das Low-Density-Lipoprotein-Cholesterin (LDL-C) senkt und gleichzeitig das High-Density-Lipoprotein-Cholesterin (HDL-C) deutlich erhöht. Das Unternehmen wurde 2019 gegründet und hat seinen Sitz in Naarden in den Niederlanden.

Navn	NewAmsterdam Pharma Company N.V.
CEO	Michael Harvey Davidson Facp.
Hjemsted	Naarden, nh Nederlandene
Websted	newamsterdampharma.com
Branche	Kemikalier
Børsnotering	09.02.2021
Medarbejdere	100